• Again, by "cure," I mean getting back to a normal life and a life free from cancer presence and free from cancer recurrence. (medscape.com)
  • DFS was defined as the interval between surgery and recurrence in the form of local recurrence or metastatic disease. (sages.org)
  • Unfortunately, up to 20 % of stage I & II disease patients will develop recurrence within five years after diagnosis. (biomedcentral.com)
  • Previous studies have suggested that several factors are associated with recurrence or reduced survival, such as carcinoembryonic antigen, epithelial growth factor receptor, and cytokeratin-19 fragment ( 3 , 4 ). (iiarjournals.org)
  • Our aim was to integrate our previously reported clinical-genetic prognostic score with new immunogenetic markers of 5-year disease-free survival (DFS) to evaluate the recurrence risk stratification before fluoropyrimidine (FL)-based adjuvant therapy. (frontiersin.org)
  • Recurrence rates were correlated with IT LVD (P survival was associated with high IT LVD (P = .0016) and IT NVD (P = .009). (bvsalud.org)
  • The incidence and timing of locoregional recurrence, distant metastatic disease, new primary malignancies and death were evaluated retrospectively. (sagepub.com)
  • Overall and disease-free survival (survival to time of first recurrence) were determined by the life table method. (sagepub.com)
  • Two hundred twenty-one patients had disease recurrence. (qxmd.com)
  • Adjuvant platinum-based chemotherapy is the current standard of care for patients with completely resected early-stage NSCLC who have a high risk for disease recurrence or relapse. (globaloncologyacademy.org)
  • According to the new trial results, treatment with atezolizumab following surgery and chemotherapy reduced the risk of disease recurrence or death by 34% in patients with stage 2-3A NSCLC whose tumors express PD-L1 ≥1%, compared with best supportive care. (globaloncologyacademy.org)
  • In the broader population of all randomized stage 2-3A study participants with NSCLC, atezolizumab reduced the risk of disease recurrence or death by 21% following a median follow-up of 32.2 months. (globaloncologyacademy.org)
  • Outcome parameters were progression-free survival (PFS), overall survival (OS) and pattern of recurrence. (lu.se)
  • Different chemotherapy timings did not differ significantly in either survival or recurrence patterns. (lu.se)
  • Tumor size, lymph node status, Ki-67 score, metastasis, overall survival (OS), and disease-free survival (DFS) were retrieved from medical records. (nih.gov)
  • An independent, central radiology review board assessed disease progression and tumor shrinkage. (amgen.com)
  • The rate (75 percent) and timing (median 7.0 weeks) of crossover from the BSC alone arm to receiving panitumumab, and the anti-tumor activity observed after crossover, likely confounded the ability to demonstrate a treatment effect on overall survival (Hazard ratio = 0.93). (amgen.com)
  • Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)
  • Significant parameters used in the determination of the prognosis and survival of esophageal cancer include tumor stage, surgical margin, and metastatic lymph node status. (researchsquare.com)
  • Background: This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning. (iiarjournals.org)
  • With NADT prior to RP, the intent is to eradicate malignant androgen-dependent cells, in the hope that sufficient tumor regression will permit complete resection of residual prostate cancer, improving pathologic outcome and survival. (medscape.com)
  • We investigated whether tumor response, disease control, progression-free survival (PFS), or time to progression (TTP) could be considered a valid surrogate for OS to assess the benefits of first-line therapies for patients with metastatic breast cancer. (eur.nl)
  • This study examines the influence of the heterogeneity of tumor proliferation on disease-free survival of patients with a breast carcinoma. (biomedcentral.com)
  • PURPOSE: To investigate the relationship of hypoxia-inducible factor-1alpha (HIF-1alpha) tumor expression in predicting the response to epirubicin and disease-free survival (DFS) in patients with breast cancer enrolled in a single institution trial of primary anthracycline and tamoxifen therapy. (ox.ac.uk)
  • The disease-free survival rate for Stage II and III cancers is slightly lower, depending on the size of the tumor and when treatment is begun. (medlineplus.gov)
  • New Phase III trial data suggests giving colon cancer patients Roche's oral anticancer drug Xeloda in combination with intravenous oxaliplatin immediately after surgery boosts disease-free survival compared with combined postsurgery chemotherapy using 5-fluorouracil/leucovorin. (genengnews.com)
  • THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
  • However, the identification of factors predicting a worse survival in stage II colon cancer led the American Society of Clinical Oncology (ASCO) [ 3 - 5 ], the Nationonal Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to define a collective of high-risk patients who may benefit from adjuvant chemotherapy. (biomedcentral.com)
  • Median progression-free survival (PFS) improved from 4.9 months with investigator's choice of chemotherapy to 7.0 months with trastuzumab duocarmazine (SYD985). (medpagetoday.com)
  • The use of adjuvant chemotherapy according to disease stage before randomization in the ADAURA trial was consistent with the uptake reported in clinical trials and with practice in the community observed in real-world studies across different regions," the authors wrote. (cgtlive.com)
  • The disease-free survival benefit with osimertinib was observed irrespective of whether patients received adjuvant chemotherapy or not," added the authors. (cgtlive.com)
  • MIBC is an aggressive disease associated with high morbidity and mortality, and life prolonging therapies include radical cystectomy, chemotherapy, radiotherapy, and immune checkpoint inhibitors ( 4 ). (frontiersin.org)
  • A combination of surgery and chemotherapy results in the long-term survival of approximately 60-70% of osteosarcoma patients [ 3 ]. (biomedcentral.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • Patients with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes shortness of breath and low oxygen levels because of lung scarring, have worse outcomes if they live in poor neighborhoods, according to research presented at the ATS 2021 International Conference. (medicalxpress.com)
  • With a disease like IPF, which has a very high mortality, we are more able to demonstrate the substantial impact that these neighborhood-level factors can have on survival and transplant outcomes. (medicalxpress.com)
  • Our results suggest that high IT LVD has a strong impact on survival outcomes in advanced stage OSCC. (bvsalud.org)
  • However, neoadjuvant therapy may provide an important paradigm for the discovery of active agents for the treatment of prostate carcinoma, in addition to improving clinical outcomes for men with early, high-risk disease. (medscape.com)
  • Eligible patients had received at least two prior therapies or T-DM1 for metastatic disease. (medpagetoday.com)
  • The study population had a median age of about 57, a median duration of metastatic disease of 3 to 3.5 years, and a median of four to five prior metastatic regimens. (medpagetoday.com)
  • Incidence of distance metastatic disease and additional cancers were also studied.ResultsMedian follow-up from treatment initiation was 26·4 months (range 1·2-84·7 months). (sagepub.com)
  • Disease-Free Survival: Endpoint for Adjuvant Therapy for Cancer? (medscape.com)
  • The article is " You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer ? (medscape.com)
  • Cite this: Disease-Free Survival: Endpoint for Adjuvant Therapy for Cancer? (medscape.com)
  • The 15-year progression-free survival was 36% with adjuvant therapy versus 29% with neoadjuvant therapy ( P = 0.01). (medscape.com)
  • Adjuvant therapy was also superior with respect to biochemical failure, distant metastasis, and metastasis-free survival. (medscape.com)
  • This result supported that FLs monotherapy is the preferred treatment for a patient with stage II disease, even if the routine administration of adjuvant therapy is not recommended in these patients. (frontiersin.org)
  • Kaplan-Meier survival analysis was used to evaluate OS and DFS. (sages.org)
  • The log rank test on the Kaplan-Meier survival analysis revealed that there was no significant difference (p=0.591) in OS between TTE (median survival=52.6 months), MIE (median survival = 39.73 months) and THE (median survival=29.71 months). (sages.org)
  • Survival analysis was performed using Kaplan Meier curves. (hindawi.com)
  • Kaplan-Meier curve for intensive care unit (ICU)-free survival. (cdc.gov)
  • A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology. (medicaldaily.com)
  • Panitumumab reduced the rate of disease progression by approximately half compared to best supportive care alone in these heavily pre-treated patients," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent, and one of the study's lead investigators. (amgen.com)
  • In an ancillary study to a SWOG (Southwest Oncology Group) trial (S8897), we investigated functional polymorphisms in 4 genes in CP pharmacokinetic pathways in relation to hematologic toxicity and disease-free survival (DFS). (arizona.edu)
  • Pivotal phase 3 data to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting found that atezolizumab (Tecentriq) extended disease-free survival (DFS) by more than one-third in patients with programmed death-ligand 1 (PD-L1)-positive, resectable early-stage lung cancer. (globaloncologyacademy.org)
  • International Classification for Disease in Oncology, 3rd ed. (lu.se)
  • A significantly higher proportion of patients were alive and free of disease progression on panitumumab at all of the scheduled time points through week 32. (amgen.com)
  • For example, after six months (week 24) approximately four times as many panitumumab-treated patients were alive and progression-free (18 percent versus five percent with BSC alone). (amgen.com)
  • Twice as many panitumumab-treated patients were alive and progression-free at week 32 (10 percent versus four percent with BSC alone). (amgen.com)
  • Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
  • Panitumumab improved progression-free survival and response rate regardless of the measured level or intensity of EGFr staining. (amgen.com)
  • Results: During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). (iiarjournals.org)
  • Rintega, which has been granted breakthrough therapy designation by the FDA, met its main goal of showing that Rintega-treated patients experienced at least six months of progression-free survival. (biopharmadive.com)
  • Treatment with SYD985 significantly improved progression-free survival in comparison with standard physician's choice treatment in patients with HER2-positive metastatic breast cancer with two prior regimens or T-DM1 (trastuzumab emtansine, Kadcyla) in the metastatic setting," she said in conclusion. (medpagetoday.com)
  • Addition of Bruton's tyrosine kinase inhibitor ibrutinib to chemoimmunotherapy prolonged progression-free survival (PFS) in patients with untreated mantle cell lymphoma (MCL). (bjh.be)
  • The progression-free survival is substantially longer than the common treatment options used today, which is an important clinical advancement. (bjh.be)
  • ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. (rxlist.com)
  • However, the NCCN notes that androgen deprivation therapy before, during, and/or after radiation prolongs survival in selected patients who are receiving radiation therapy only. (medscape.com)
  • Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. (cdc.gov)
  • However, the NCCN notes that androgen deprivation therapy before, during, and/or after radiation prolongs survival in selected radiation-managed patients. (medscape.com)
  • Patients with resectable disease then underwent minimally invasive esophagectomy (MIE). (hindawi.com)
  • Long-term survival and state of health after paediatric intensive care. (bmj.com)
  • Because of the well-documented propensity for late recurrences, long-term survival should be considered in terms of a 10-year follow-up after treatment of the thymoma. (medscape.com)
  • Future considerations for the ADAURA trial include subsequent treatment, longitudinal assessment of minimal residual disease, and acquired resistance mechanisms at relapse," the authors noted. (cgtlive.com)
  • With a short postprogression survival and a moderate correlation between PFS and OS, there is no evidence that PFS is a valid surrogate endpoint for OS in malignant mesothelioma. (nih.gov)
  • The primary analysis showed no significant differences in disease-free survival, with a median duration of 5.8 years (interquartile range [IQR] = 1.6-8.2 years) for sunitinib (hazard ratio [HR] = 1.02, P = .8038, vs placebo), 6.1 years (IQR = 1.7 years to not estimable) for sorafenib (HR = 0.97, P = .7184, vs placebo), and 6.6 years (IQR = 1.5 years to not estimable) for placebo. (ascopost.com)
  • Association of the initial RT-PCR Ct values with disease duration was assessed by adjusted linear regression approach. (bvsalud.org)
  • Ocular toxicity is the most prevalent safety event, and ILD [interstitial lung disease]/pneumonitis was reported, including grade 3 or worse, in 2.4% of patients. (medpagetoday.com)
  • No other associations between single nucleotide polymorphisms and toxicity or survival were found in the treated or untreated group. (arizona.edu)
  • The aim of this study was to compare survival and toxicity after completed hysterectomy followed by adjuvant (chemo-)radiotherapy versus abandoned hysterectomy and primary treatment with chemoradiotherapy (CRT). (amsterdamumc.org)
  • The conclusion of this article by Sobrero and colleagues is that, in the adjuvant and neoadjuvant setting, disease-free survival is the primary variable. (medscape.com)
  • Patients with locally advanced disease (patients with T3 or above and/or N1 disease) require neoadjuvant chemoradiotherapy prior to surgical intervention. (hindawi.com)
  • Introduction Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease, progressive in the majority of cases. (bmj.com)
  • Conclusion In our big cohort of patients affected by primary sclerosing cholangitis, use of AZA and steroids before LT significantly prolonged transplant free survival. (bmj.com)
  • The primary objective was to compare disease-free survival between each experimental group and placebo in the intention-to-treat population. (ascopost.com)
  • The primary hypothesis was that disease-free survival (DFS), with 3 years of follow-up, is an appropriate primary end point to replace OS with 5 years of follow-up. (ox.ac.uk)
  • Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. (ox.ac.uk)
  • The presence of ITC was associated with a significantly worse disease-free survival (hazard ratio = 4.73, p = 0.005). (biomedcentral.com)
  • Response and disease control log ORs and PFS and TTP log hazard ratios were poorly correlated with log hazard ratios for OS, but the confidence limits of rho were too wide to be informative. (eur.nl)
  • People are more likely to develop IPF or other forms of interstitial lung disease (ILD) if they have worked in an occupation that has significant exposure to airborne materials. (medicalxpress.com)
  • Patients with positive lymph node status have worse survival after CRS-HIPEC, which is probably due to higher rates of systemic failure. (lu.se)
  • The resulting USPHS/IDSA guidelines were published in 1995 in the MMWR, Clinical Infectious Diseases, and the Annals of Internal Medicine, with an accompanying editorial in the Journal of the American Medical Association (1-4). (cdc.gov)
  • This review describes current considerations in the use of hydroxyurea for the management of sickle cell disease in the context of clinical severity. (cdc.gov)
  • Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
  • Number two is time free from cancer, ostensibly experiencing normal life for as long as possible. (medscape.com)
  • Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study's main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney cancer. (curetoday.com)
  • A study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) - two immunotherapy agents - did not meet its main goal of disease-free survival (time a patient survives after treatment without signs or symptoms of their cancer) in certain patients with kidney cancer, according to Bristol Myers Squibb, the manufacturer of the drugs. (curetoday.com)
  • Even with notable progress in the treatment of metastatic (kidney cancer), there are still limited treatment options available for patients with localized disease," Dr. Dana Walker, vice president and development program lead of genitourinary cancers at Bristol Myers Squibb, said in a press release. (curetoday.com)
  • Currently, the average five-year survival rate for patients with metastatic or advanced kidney cancer is 14%, and just over half of patients with resectable, localized disease experience a five-year disease-free survival. (curetoday.com)
  • Opdivo and Opdivo-based combinations have shown survival benefits in several earlier-stage and advanced cancers, including genitourinary tumors, and we are disappointed that the final analysis of CheckMate-914 Part A did not show this same benefit for the post-surgical treatment of patients with localized (kidney cancer)," Walker said. (curetoday.com)
  • Disease-Free Survival: How Does Exercising Impact Colon Cancer? (coloncancerfoundation.org)
  • https://coloncancerfoundation.org/wp-content/uploads/2022/10/jzyhmzuvur474dyzuiga.jpg 389 600 [email protected] https://coloncancerfoundation.org/wp-content/uploads/2017/01/CCCF_Logo_Final_Color.png [email protected] 2023-10-24 09:36:52 2023-10-24 09:36:52 Disease-Free Survival: How Does Exercising Impact Colon Cancer? (coloncancerfoundation.org)
  • Our findings showed that monocyte count is a prognostic factor affecting disease-free survival in patients with esophageal cancer, regardless of histological subtype. (researchsquare.com)
  • In the present study, we aimed to investigate whether the monocyte count measured at the time of diagnosis can be used as a new prognostic biomarker in predicting disease-free survival in patients with esophageal cancer. (researchsquare.com)
  • In addition, despite considerable advances in prostate cancer research, high-risk, localized prostate cancer remains an extremely refractory disease. (medscape.com)
  • ORLANDO-Aggressive treatment of early-stage prostate cancer (PCa) confers no survival benefit in men with Charlson scores of 3 or higher, researchers reported at the American Urological Association 2014 annual meeting . (renalandurologynews.com)
  • Study findings were recently published online ahead of print in Cancer , where the authors wrote: "Our study provides evidence that the cancer-specific survival benefit of aggressive treatment wanes with increasing comorbidity burden at diagnosis. (renalandurologynews.com)
  • New data from a mid-stage trial on Celldex Therapeutics' brain cancer vaccine, Rintega (rindopepimut), demonstrates that combining it with Avastin improves patients' chances of survival significantly. (biopharmadive.com)
  • Interim analysis results from the double-blind, phase 3 ADAURA trial demonstrated that among patients with stage IB to IIIA EGFR -positive non-small cell lung cancer (NSCLC), disease-free survival was significantly longer among those who received osimertinib (Tagrisso) than among those who received placebo. (cgtlive.com)
  • According to Michael Wang, MD, of MD Anderson Cancer Centre in Houston, "The SHINE study is the first international phase III trial to show a positive impact of ibrutinib combined with standard-of-care treatment in this disease. (bjh.be)
  • Nevertheless, the 5-year survival rate for nonmetastatic MIBC patients (75% of newly diagnosed bladder cancer) is only 36% - 48% after first-line treatment, while the 5-year relative survival is 5% - 36% in metastatic MIBC ( 3 ). (frontiersin.org)
  • These results lay the groundwork for a new approach to the treatment of early-stage lung cancer and bring us closer to our goal of providing an effective and tailored treatment option for every person diagnosed with this disease. (globaloncologyacademy.org)
  • Pivotal Phase III Data at ASCO Show Genentech's Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning [news release]. (globaloncologyacademy.org)
  • A study conducted by the Memorial Sloan-Kettering Cancer Center reported 5-year and 10-year survival rates for various stages of thymomas (see Table 1 below). (medscape.com)
  • Reda Wilson has worked in cancer prevention and control more than 30 years, including 18 years at the Centers for Disease Control and Prevention's (CDC) Division of Cancer Prevention and Control. (cdc.gov)
  • I hope that over the next 30 years, NPCR and CDC increase our cancer surveillance, expand prevention resources, and continue to push toward a future free of cancer. (cdc.gov)
  • I'm pleased when I see reports showing decreasing cancer rates and improved survival. (cdc.gov)
  • People undergoing cancer treatment hope for the best outcome and the longest survival with the highest quality of life. (msdmanuals.com)
  • A study conducted by the Memorial Sloan-Kettering Cancer Center reported 5-year and 10-year survival rates to corresponding stages of thymomas (see Table 1 below). (medscape.com)
  • Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by imaging within the 28 days prior to randomization. (who.int)
  • Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. (umassmed.edu)
  • In these patients, panitumumab treatment resulted in a nine percent partial response and 32 percent stable disease, as well as one complete response. (amgen.com)
  • Cox regression analysis revealed that factors associated with transplant free survival were: AZA use before transplantation (p = 0.012, OR 2.3, 95% CI 1.2-4.4), treatment with steroids pre-LT (p = 0.001, OR 4.7, 95% CI 2.2-10.1) and concomitant IBD (p = 0.023. (bmj.com)
  • Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase III study. (ascopost.com)
  • Adjuvant treatment is usually reserved to stage III disease. (biomedcentral.com)
  • The study demonstrated that the risk of other-cause mortality far outweighs the absolute risk reduction associated with aggressive versus non-aggressive treatment in older men with a high burden of comorbid disease. (renalandurologynews.com)
  • However, the researchers said this treatment only provides a 4% to 5% improvement in 5-year survival compared with observation. (globaloncologyacademy.org)
  • https://zhangzhiqiao8.shinyapps.io/Artificial_Intelligence_Survival_Prediction_for_CRC_B1005_1/ , which was valuable for individualized treatment decision before surgery. (biomedcentral.com)
  • This treatment has greatly improved survival for people with both seminomas and nonseminomas. (medlineplus.gov)
  • In particular, the difference of mean survival times quantifies the average survival benefit for a patient receiving a new treatment compared with a patient treated with standard of care, whereas the net benefit quantifies the probability of a patient receiving the new treatment to live longer by at least m months (for any number of months m of interest) than a patient receiving the standard treatment. (medscape.com)
  • I was surprised that we were able to find a significant impact of neighborhood-level disadvantage on survival in our relatively small cohort of patients with IPF. (medicalxpress.com)
  • Study investigators also reported that panitumumab significantly improved disease control versus BSC alone (36 percent versus 10 percent, respectively), as measured by response rate and stable disease. (amgen.com)
  • The stable disease rate was 28 percent with panitumumab versus 10 percent with BSC alone. (amgen.com)
  • A significant increase in organ-confined disease and a decrease in the incidence of positive margins have also been reported. (medscape.com)
  • In HIV-infected men who have sex with men, Pneumocystis carinii pneumonia (PCP), toxoplasmic encephalitis, fungal infections, and disseminated Mycobacterium avium complex (MAC) disease have decreased in incidence (9). (cdc.gov)
  • Liver fibrosis is a chronic, highly prevalent disease that may progress to cirrhosis and substantially increases the risk for development of hepatocellular carcinoma (HCC). (mdpi.com)
  • Undernutrition is responsible for one third of all child deaths and contributes substantially to the global burden of disease. (who.int)
  • The 15-year survival rate is 12.5% for a person with an invasive thymoma and 47% for a person with a noninvasive thymoma. (medscape.com)
  • Patients with concomitant IBD had an increased transplant free survival compared to those without IBD. (bmj.com)
  • Consequently, despite the large number with health impairment before admission, cumulative one year survival was favourable and health status in three quarters of the population was preserved. (bmj.com)
  • The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. (cdc.gov)
  • Furthermore, the difference in objective response rates and the proportion of patients with disease stabilization between panitumumab and best supportive care alone demonstrated the significant activity of this agent. (amgen.com)
  • Significant survival genes were analyzed by GEPIA2. (frontiersin.org)
  • Adding oxaliplatin (OXA) to therapy based on FLs (5-FU and capecitabine) further improves the disease-free (DFS) and OS rates in patients with stage III disease. (frontiersin.org)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. (cdc.gov)